New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
05:34 EDTMRK, PFE, BAYRYFDA: Bayer's Aleve may carry lower cardiac risk than others, WSJ reports
The FDA says that a review of popular painkillers found that naproxen, sold as Aleve by Bayer, may carry a lower cardiac risk than similar painkilling drugs, reports the Wall Street Journal.Reference Link
News For BAYRY;PFE;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTMRK, PFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
11:24 EDTPFEPfizer says Ibrance application validated by EMA
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
August 14, 2015
08:36 EDTPFEPfizer's pending Hospira acquisition approved by Canadian Competition Bureau
Pfizer (PFE) announced that it received approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada. "We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira," said Ian Read, chairman and CEO of Pfizer. "We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015."
08:35 EDTPFEHayman takes Mylan, Perrigo stakes, boasts exposure to energy
Subscribe for More Information
08:26 EDTPFEPiper says Street $4B too low on Pfizer 2019 sales estimates
Piper Jaffray analyst Richard Purkiss believes the Street is underestimating Pfizer's 2019 sales by $4B. The consensus 2019 revenue estimate is $58.7B. Analysts are factoring in "overly conservative" growth assumptions for five of Pfizer's key brands, namely Prevnar, Ibrance, Xeljanz, Eliquis and Lyrica, Purkiss tells investors in a research note. Sentiment towards the stock will "improve meaningfully" as investors "wake up" to the sales turnaround from 2015, the analyst believes. Purkiss expects Pfizer's 36% discount to his $48 target price to close as sentiment improves and reiterates an Overweight rating on the pharma giant. The stock end yesterday's trading down 1c to $35.36.
August 13, 2015
10:55 EDTMRKBMO upgrades Merck on Alzheimer's, lung cancer drug prospects
Subscribe for More Information
10:00 EDTMRKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A. Schulman (SHLM) upgraded to Buy from Accumulate at Global Hunter... American Capital Agency (AGNC) upgraded to Buy from Neutral at Compass Point... Annaly Capital (NLY) upgraded to Buy from Neutral at Compass Point... Aramark (ARMK) upgraded to Outperform at Baird... Bernstein upgrades Yahoo (YHOO), says shares pricing in 'almost' worst case scenario... BreitBurn Energy (BBEP) upgraded to Neutral from Sell at UBS... CAE (CAE) upgraded to Buy from Hold at Desjardins... Capital One (COF) upgraded at Argus... Coca-Cola Enterprises (CCE) upgraded to Outperform from Underperform at CLSA... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... EZchip (EZCH) upgraded to Buy from Hold at Brean Capital... Enzymotec (ENZY) upgraded to Outperform from Market Perform at Wells Fargo... Extra Space Storage (EXR) upgraded on positive catalysts at BMO Capital... Green Plains (GPRE) upgraded to Buy from Neutral at Goldman... Legg Mason (LM) upgraded to Overweight from Equal Weight at Barclays... Lincoln National (LNC) upgraded to Overweight at Morgan Stanley... Merck (MRK) upgraded on improved pipeline outlook at BMO Capital... Microsoft (MSFT) upgraded to Buy from Hold at Stifel... Monster Beverage (MNST) upgraded to Overweight from Equal Weight at Morgan Stanley... National Research (NRCIB) upgraded to Overweight from Equal-Weight at First Analysis... Qlik Technologies (QLIK) upgraded to Buy from Hold at Deutsche Bank... Spectra Energy Partners (SEP) upgraded to Overweight from Neutral at JPMorgan... Yahoo (YHOO) upgraded to Outperform from Market Perform at Bernstein.
08:33 EDTMRKMerck upgraded on improved pipeline outlook at BMO Capital
As noted earlier, BMO Capital upgraded Merck to Outperform from Market Perform. The firm has become more upbeat on the company's pipeline and predicts that upcoming data wil raise the Street's expectations for the company, leading to multiple expansion. The firm is impressed with the company's recent commercial execution and is upbeat on the company's near-term and long-term outlook. Target to $70 from $65.
08:16 EDTPFEPfizer receives approval from ACCC for pending acquisition of Hospira
Pfizer (PFE) announced that the Australian Competition and Consumer Commission has approved the company's pending acquisition of Hospira (HSP) and found no need for remedies. Completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions. Pfizer continus to expect the transaction to close in the second half of 2015.
08:01 EDTMRKMerck, MD Anderon Cancer Center partner to evaluate Keytruda treatment
Subscribe for More Information
06:29 EDTMRKMerck upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use